tetano
Editor, Senior Moderator
Sci Rep
. 2021 Mar 15;11(1):5934.
doi: 10.1038/s41598-021-85202-9.
SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals
Shota Yoshida[SUP] 1 2 [/SUP], Chikako Ono[SUP] 3 [/SUP], Hiroki Hayashi[SUP] 1 [/SUP], Shinya Fukumoto[SUP] 4 [/SUP], Satoshi Shiraishi[SUP] 5 [/SUP], Kazunori Tomono[SUP] 6 [/SUP], Hisashi Arase[SUP] 7 8 [/SUP], Yoshiharu Matsuura[SUP] 3 [/SUP], Hironori Nakagami[SUP] 9 [/SUP]
Affiliations
Abstract
The aim of this study is to understand adaptive immunity to SARS-CoV-2 through the analysis of B cell epitope and neutralizing activity in coronavirus disease 2019 (COVID-19) patients. We obtained serum from forty-three COVID-19 patients from patients in the intensive care unit of Osaka University Hospital (n = 12) and in Osaka City Juso Hospital (n = 31). Most individuals revealed neutralizing activity against SARS-CoV-2 assessed by a pseudotype virus-neutralizing assay. The antibody production against the spike glycoprotein (S protein) or receptor-binding domain (RBD) of SARS-CoV-2 was elevated, with large individual differences, as assessed by ELISA. We observed the correlation between neutralizing antibody titer and IgG, but not IgM, antibody titer of COVID-19 patients. In the analysis of the predicted the linear B cell epitopes, hot spots in the N-terminal domain of the S protein were observed in the serum from patients in the intensive care unit of Osaka University Hospital. Overall, the analysis of antibody production and B cell epitopes of the S protein from patient serum may provide a novel target for the vaccine development against SARS-CoV-2.
. 2021 Mar 15;11(1):5934.
doi: 10.1038/s41598-021-85202-9.
SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals
Shota Yoshida[SUP] 1 2 [/SUP], Chikako Ono[SUP] 3 [/SUP], Hiroki Hayashi[SUP] 1 [/SUP], Shinya Fukumoto[SUP] 4 [/SUP], Satoshi Shiraishi[SUP] 5 [/SUP], Kazunori Tomono[SUP] 6 [/SUP], Hisashi Arase[SUP] 7 8 [/SUP], Yoshiharu Matsuura[SUP] 3 [/SUP], Hironori Nakagami[SUP] 9 [/SUP]
Affiliations
- PMID: 33723294
- DOI: 10.1038/s41598-021-85202-9
Abstract
The aim of this study is to understand adaptive immunity to SARS-CoV-2 through the analysis of B cell epitope and neutralizing activity in coronavirus disease 2019 (COVID-19) patients. We obtained serum from forty-three COVID-19 patients from patients in the intensive care unit of Osaka University Hospital (n = 12) and in Osaka City Juso Hospital (n = 31). Most individuals revealed neutralizing activity against SARS-CoV-2 assessed by a pseudotype virus-neutralizing assay. The antibody production against the spike glycoprotein (S protein) or receptor-binding domain (RBD) of SARS-CoV-2 was elevated, with large individual differences, as assessed by ELISA. We observed the correlation between neutralizing antibody titer and IgG, but not IgM, antibody titer of COVID-19 patients. In the analysis of the predicted the linear B cell epitopes, hot spots in the N-terminal domain of the S protein were observed in the serum from patients in the intensive care unit of Osaka University Hospital. Overall, the analysis of antibody production and B cell epitopes of the S protein from patient serum may provide a novel target for the vaccine development against SARS-CoV-2.